Table 1.

Aggrephagy enhancers for the treatment of AD.

Compound	Mode of Action	Animal Model	Dose/Route	Result	Reference
Curcumin	mTOR inhibition	APP/PS1	1000 ppm/P.O.	↓Aβ plaques, ↑Memory	[130,150]
Rapamycin	mTOR inhibition	PDAPP mice hAPP (J20) mice P301S mice	2.24 mg/kg/P.O. 2.24 mg/kg/P.O. 15 mg/kg/I.P.	↓Aβ plaques, ↑Memory ↓Cerebral amyloid angiopathy,↑Memory ↓Sarkosyl insoluble tau	[144,146,180]
Temsirolimus	mTOR inhibition	P301S mice Tg30 mice	20 mg/kg/I.P. 0.2 mg/kg/I.P.	↓Sarkosyl insoluble tau, ↑Memory ↓Sarkosyl insoluble tau, ↑Motor function	[148,181]
Oleuropein	AMPK activation, mTOR inhibition	TgCRND8 mice	50 mg/kg/P.O.	↓Aβ plaques, ↑Memory	[159]
Methylene blue	mTOR inhibition	JNPL3 mice	0.02 mg/kg/P.O.	↓Sarkosyl insoluble tau	[161]
Ouabain	mTOR inhibition, TFEB activation	P301L mice	1.5 µgm/kg/I.P.	↓Sarkosyl insoluble tau, ↑Memory	[176]
Trehalose	TFEB activation	P301S mice APP/PS1 mice	2% Trehalose in drinking water 5 µL injected into brain lateral ventricles	↓Sarkosyl insoluble tau, ↑Motor function ↓Aβ deposits, ↑Memory	[170,173,174]
Pseudoginsenoside-F11 (PF-11)	TFEB activation	SAMP8 mice	32 mg/kg/P.O.	↓Aβ plaques, ↑Memory	[182,183]
Hep-14	TFEB activation	APP/PS1 mice	5 mg/kg/I.P.	↓Aβ plaques	[177]
Aspirin	PPARGC1α mediated TFEB activation	5xFAD mice	2 mg/kg/P.O.	↓Aβ plaques	[179]
Cinnamic acid	PPARGC1α mediated TFEB activation	5xFAD mice	100 mg/kg/P.O.	↓Aβ plaques, ↑Memory, ↑Open field exploration	[178]

P.O: Oral route; I.P: Intraperitoneal route; PPM: parts per million.